Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report

Introduction: We discuss a case of massive hemoptysis in the setting of a direct-acting oral anticoagulant (DOAC) successfully managed with nebulized tranexamic acid (TXA). Case Report: Per the American College of Cardiology and the American Society of Hematology, it is recommended that significant...

Full description

Bibliographic Details
Main Authors: Jacqueline M. Dempsey, Mandy Jones, Jonathan Bronner, Connor Greer, Gavin T. Howington
Format: Article
Language:English
Published: eScholarship Publishing, University of California 2020-11-01
Series:Clinical Practice and Cases in Emergency Medicine
Online Access:https://escholarship.org/uc/item/12n4q5j4
id doaj-4dcf462952a54f48ac8bb5f431770d2e
record_format Article
spelling doaj-4dcf462952a54f48ac8bb5f431770d2e2020-11-25T04:10:43ZengeScholarship Publishing, University of CaliforniaClinical Practice and Cases in Emergency Medicine2474-252X2020-11-014410.5811/cpcem.2020.7.48525cpcem-04-572Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case ReportJacqueline M. Dempsey0Mandy Jones1Jonathan Bronner2Connor Greer3Gavin T. Howington4University of Kentucky HealthCare, Department of Pharmacy Services, Lexington, KentuckyUniversity of Kentucky, Department of Pharmacy Practice and Science, Lexington, KentuckyUniversity of Kentucky HealthCare, Department of Emergency Medicine, Lexington, KentuckyUniversity of Kentucky HealthCare, Department of Emergency Medicine, Lexington, KentuckyUniversity of Kentucky HealthCare, Department of Pharmacy Services, Lexington, KentuckyIntroduction: We discuss a case of massive hemoptysis in the setting of a direct-acting oral anticoagulant (DOAC) successfully managed with nebulized tranexamic acid (TXA). Case Report: Per the American College of Cardiology and the American Society of Hematology, it is recommended that significant bleeding associated with a DOAC be treated with either 4-factor prothrombin complex concentrate or andexanet alfa. However, our patient was at high risk for thrombotic complications given a recent pulmonary embolism. Conclusion: We demonstrate that it is reasonable to trial nebulized TXA given its low cost, ease of administration, and safety profile. Additionally, this report discusses a unique dosing strategy and a previously unreported complication associated with nebulization of undiluted TXA.https://escholarship.org/uc/item/12n4q5j4
collection DOAJ
language English
format Article
sources DOAJ
author Jacqueline M. Dempsey
Mandy Jones
Jonathan Bronner
Connor Greer
Gavin T. Howington
spellingShingle Jacqueline M. Dempsey
Mandy Jones
Jonathan Bronner
Connor Greer
Gavin T. Howington
Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report
Clinical Practice and Cases in Emergency Medicine
author_facet Jacqueline M. Dempsey
Mandy Jones
Jonathan Bronner
Connor Greer
Gavin T. Howington
author_sort Jacqueline M. Dempsey
title Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report
title_short Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report
title_full Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report
title_fullStr Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report
title_full_unstemmed Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report
title_sort inhaled tranexamic acid for massive hemoptysis in the setting of oral anticoagulation: a case report
publisher eScholarship Publishing, University of California
series Clinical Practice and Cases in Emergency Medicine
issn 2474-252X
publishDate 2020-11-01
description Introduction: We discuss a case of massive hemoptysis in the setting of a direct-acting oral anticoagulant (DOAC) successfully managed with nebulized tranexamic acid (TXA). Case Report: Per the American College of Cardiology and the American Society of Hematology, it is recommended that significant bleeding associated with a DOAC be treated with either 4-factor prothrombin complex concentrate or andexanet alfa. However, our patient was at high risk for thrombotic complications given a recent pulmonary embolism. Conclusion: We demonstrate that it is reasonable to trial nebulized TXA given its low cost, ease of administration, and safety profile. Additionally, this report discusses a unique dosing strategy and a previously unreported complication associated with nebulization of undiluted TXA.
url https://escholarship.org/uc/item/12n4q5j4
work_keys_str_mv AT jacquelinemdempsey inhaledtranexamicacidformassivehemoptysisinthesettingoforalanticoagulationacasereport
AT mandyjones inhaledtranexamicacidformassivehemoptysisinthesettingoforalanticoagulationacasereport
AT jonathanbronner inhaledtranexamicacidformassivehemoptysisinthesettingoforalanticoagulationacasereport
AT connorgreer inhaledtranexamicacidformassivehemoptysisinthesettingoforalanticoagulationacasereport
AT gavinthowington inhaledtranexamicacidformassivehemoptysisinthesettingoforalanticoagulationacasereport
_version_ 1724419453933846528